罗氟司特对慢性阻塞性肺疾病抗炎效应的ROBERT随机对照试验
ROBERT是一项在5国18中心开展的为期16周的随机双盲安慰剂对照试验,纳入158例中重度COPD伴慢性支气管炎患者,评估罗氟司特500μg每日一次对支气管黏膜炎症的影响。结果显示,罗氟司特未显著改变支气管黏膜下CD8细胞数量,但显著减少支气管活检和诱导痰中的嗜酸性粒细胞,提示其疗效可能由肺部嗜酸性粒细胞介导。
要点
- 罗氟司特500μg每日一次治疗16周未显著减少支气管黏膜下CD8细胞。
- 罗氟司特显著降低支气管活检和诱导痰中的嗜酸性粒细胞,但外周血嗜酸性粒细胞无显著变化。
- 常见中度不良事件为COPD加重、咳嗽、腹泻和鼻咽炎,组间差异不大。
核心结论
- 16周罗氟司特治疗未显著改变中重度COPD患者支气管黏膜下CD8细胞数量。
- 罗氟司特显著减少支气管活检和诱导痰中的嗜酸性粒细胞,提示其疗效可能由肺部嗜酸性粒细胞介导。
研究设计与样本
- 随机、双盲、安慰剂对照试验,在5国18个中心开展。
- 纳入158例40-80岁、中重度COPD伴慢性支气管炎患者,按1:1随机分配至罗氟司特500μg每日一次组或安慰剂组,治疗16周。
- 主要终点为意向治疗人群中支气管活检黏膜下CD8细胞数量从随机化至第16周的变化。
主要发现
- 常见中度不良事件(>5%患者)包括COPD加重(罗氟司特组3例[4%] vs 安慰剂组7例[9%])、咳嗽(6例[8%] vs 4例[5%])、腹泻(4例[5%] vs 3例[4%])和鼻咽炎(3例[4%] vs 5例[6%])。
- 严重不良事件发生于罗氟司特组8例(10%)和安慰剂组5例(6%),研究期间无死亡。
关键数值与推荐
- 纳入标准:年龄40-80岁、COPD、既往两年每年慢性咳痰3个月、支气管舒张后FEV1占预计值30-80%、支气管舒张后FEV1/FVC≤70%。
- 排除合并使用吸入糖皮质激素,随机化按是否联用长效β2受体激动剂分层。
- 罗氟司特剂量为500μg每日一次,治疗16周。
临床怎么用
- 罗氟司特可能通过减少肺部嗜酸性粒细胞发挥抗炎作用,支持其在中重度COPD伴慢性支气管炎患者中的应用。
- 外周血嗜酸性粒细胞未显著变化,提示疗效监测可能需要关注肺部局部炎症而非仅依赖外周血指标。
局限性
- 研究未发现罗氟司特对CD8细胞等主要炎症细胞有显著影响,抗炎机制尚未完全阐明。
- 研究周期为16周,长期抗炎效应未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical effects of roflumilast, a selective phosphodiesterase-4 inhibitor, are well established, but little is known about the anti-inflammatory mechanisms underlying the drug's efficacy. The aim of the ROflumilast Biopsy European Research Trial (ROBERT) was to assess the anti-inflammatory effects of roflumilast on bronchial mucosal inflammation in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) and chronic bronchitis. METHODS: ROBERT was a randomised, double-blind, placebo-controlled trial done at 18 sites in five countries. Eligible patients were aged 40-80 years, had COPD, and had had a chronic productive cough for 3 months in each of the two previous years. Patients also had to have a post-bronchodilator predicted FEV1 30-80% and a post-bronchodilator FEV1/forced vital capacity ratio of 70% or less. Patients entered a 6-week run-in period before being randomly assigned (1:1) via a computerised central randomisation system to roflumilast 500 μg once daily or placebo for 16 weeks, in addition to bronchodilator therapy (inhaled corticosteroids were not permitted). Randomisation was stratified by concomitant use of long-acting β agonist. Both participants and investigators were masked to group assignment. Roflumilast and placebo were supplied as identical yellow, triangular tablets. Airway inflammation was assessed by quantification of inflammatory cells in bronchial biopsy samples and induced sputum samples. The primary endpoint was the change in the number of CD8 inflammatory cells in bronchial biopsy submucosa from randomisation to week 16 in the intention-to-treat population. Changes in cell counts of additional inflammatory markers, including eosinophils, were assessed as secondary endpoints. This trial is registered with ClinicalTrials.gov, number NCT01509677, and is closed to new participants, with follow-up completed. FINDINGS: Between Jan 4, 2012, and Feb 11, 2016, 158 patients were randomly assigned: 79 to the roflumilast group, and 79 to the placebo group. At week 16, the change in the number of CD8 cells in the bronchial submucosa did not differ significantly between the roflumilast and placebo groups (treatment ratio 1·03 [95% CI 0·82-1·30]; p=0·79). However, compared with placebo, roflumilast was associated with a significant reduction in eosinophils in bronchial biopsy samples at week 16 (treatment ratio 0·53 [95% CI 0·34-0·82]; p=0·0046). Significant reductions in both absolute (p=0·0042) and differential (p=0·0086) eosinophil cell counts in induced sputum were also noted with roflumilast compared with placebo, but peripheral blood eosinophil counts were not significantly affected. We noted no other significant effects of roflumilast on bronchial mucosal inflammatory cells. The most common (ie, occurring in >5% patients) moderate adverse events were worsening of COPD (three [4%] patients in the roflumilast group vs seven [9%] in the placebo group), cough (six [8%] vs four [5%]), diarrhoea (four [5%] vs three [4%]), and nasopharyngitis (three [4%] vs five [6%]). Severe adverse events included worsening of COPD, which occurred in four (5%) patients in the roflumilast group and two (3%) in the placebo group. No deaths occurred during the study. Serious adverse events occurred in eight (10%) patients in the roflumilast group and five (6%) in the placebo group. INTERPRETATION: 16 weeks of treatment with roflumilast did not affect the number of CD8 cells in bronchial submucosa compared with placebo. However, we noted significant reductions in eosinophil cell counts in bronchial biopsy samples and induced sputum, generating the hypothesis that the effect of roflumilast in COPD could be mediated by an effect on lung eosinophils. FUNDING: Takeda and AstraZeneca.
引用
- Rabe KF, Watz H, Baraldo S, et al. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial. Lancet Respir Med. 2018. PMID: 30224319. doi:10.1016/S2213-2600(18)30331-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。